SCHEMBL23320398

SCHEMBL23320398

Cc1cc(C)c(S(=O)(=O)[O-])c(C)c1.N[n+]1cc(F)cc(Br)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAPGEF4 Q8WZA2 5/20 0.35
▸ FFAR4 Q5NUL3 1/20 0.34
▸ F2 P00734 3/20 0.33
▸ PRSS1 P07477 3/20 0.33
▸ PRSS2 P07478 3/20 0.33
▸ PRSS3 P35030 3/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA2 P00918 2/20 0.33
▸ MMP1 P03956 1/20 0.33
▸ MMP2 P08253 1/20 0.33
▸ MMP9 P14780 1/20 0.33
▸ MMP8 P22894 1/20 0.33
▸ MMP13 P45452 1/20 0.33
▸ MAPK1 P28482 1/20 0.32
▸ NR3C1 P04150 1/20 0.31
▸ PGR P06401 1/20 0.31
▸ NR3C2 P08235 1/20 0.31
▸ CA12 O43570 1/20 0.30
▸ CA7 P43166 1/20 0.30
▸ CA13 Q8N1Q1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20874147 0.90 RAPGEF4 (0.40) RAPGEF4FFAR4F2PRSS1PRSS2
SCHEMBL31153489 0.87 RAPGEF4 (0.38) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL16913904 0.84 RAPGEF4 (0.36) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL1900032 0.81 RAPGEF4 (0.44) RAPGEF4FFAR4F2PRSS1PRSS2
SCHEMBL29504768 0.81 RAPGEF4 (0.44) RAPGEF4FFAR4F2PRSS1PRSS2
SCHEMBL3199564 0.78 RAPGEF4 (0.38) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL1290843 0.77 RAPGEF4 (0.38) RAPGEF4FFAR4F2PRSS1PRSS2
SCHEMBL23755575 0.77 F2 (0.37) RAPGEF4FFAR4F2PRSS1PRSS2
SCHEMBL29942396 0.77 F2 (0.37) RAPGEF4FFAR4F2PRSS1PRSS2
SCHEMBL25283314 0.77 F2 (0.37) RAPGEF4F2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055363-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2026-05-15 — — CN disclosed
EP-4724438-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2026-04-15 — — EP disclosed
WO-2024259015-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2024-12-19 — — WO disclosed
CN-114478519-B Pyrazolopyridine compound or salt thereof, and preparation method and application thereof 励缔(杭州)医药科技有限公司 2024-06-11 — — CN disclosed
CN-114181205-B Pyrazolopyridine compound or salt thereof, and preparation method and application thereof 励缔(杭州)医药科技有限公司 2024-06-11 — — CN disclosed
CN-112654608-B Fused ring compound having urea structure 桑福德伯纳姆普利斯医学发现研究所 2024-05-07 — — CN disclosed
CN-114478519-A Pyrazolopyridine compound or salt thereof, and preparation method and application thereof 上海辉启生物医药科技有限公司 2022-05-13 — — CN disclosed
CN-114181205-A Pyrazolopyridine compound or salt thereof, and preparation method and application thereof 上海辉启生物医药科技有限公司 2022-03-15 — — CN disclosed
EP-3818053-A1 FUSED RING COMPOUND HAVING UREA STRUCTURE Sanford Burnham Prebys Medical Discovery Institute (US) 2021-05-12 — — EP disclosed
CN-112654608-A Condensed ring compounds having urea structure 桑福德伯纳姆普利斯医学发现研究所 2021-04-13 — — CN disclosed
Send feedback